Go to the list of all blogs
Anna G's Avatar
published in Blogs
May 24, 2023
Xtrackers Russell US Multifactor ETF (DEUS): Riding the Momentum Wave with Ascending Momentum Indicator

Xtrackers Russell US Multifactor ETF (DEUS): Riding the Momentum Wave with Ascending Momentum Indicator

At Tickeron, we believe in unleashing the power of artificial intelligence to enhance trading decisions, and our marketing team plays a pivotal role in sharing this vision with the world.

Step into the world of Xtrackers Russell US Multifactor ETF (DEUS) as we uncover an intriguing development in its momentum. On May 22, 2023, DEUS's Momentum indicator climbed above the crucial 0 level, signifying a potential uptrend in the stock's price. In this blog post, we delve into the significance of this momentum surge and unlock the valuable insights provided by A.I.dvisor, offering statistical evidence of a high probability of success based on historical backtesting.

Understanding the Momentum Indicator: Before we explore the implications of DEUS's momentum shift, let's take a moment to understand the concept of the Momentum indicator. This technical tool compares the current price of a stock to its price at a previous point in time, typically 14 days ago. It measures the strength and velocity of price movements, providing insights into the stock's momentum and potential direction.

DEUS Rides the Momentum Wave: The recent ascent of DEUS's Momentum indicator above the 0 level carries significant implications for investors. This upward movement suggests that the stock's price has the momentum to continue its upward trajectory. In fact, the current price surpasses the price logged 14 days ago, further reinforcing the positive momentum signal. Traders and investors may consider capitalizing on this trend by buying the stock or exploring call options.

Data-Driven Insights from A.I.dvisor: A.I.dvisor, utilizing its sophisticated algorithms, backtested historical data to shed light on the potential success of DEUS's momentum surge. Out of 75 similar cases identified by A.I.dvisor, an impressive 63 of them resulted in successful outcomes. This statistically significant success rate of 84% adds weight to the potential profitability of riding the momentum wave with DEUS.

Investing with Confidence: While the ascending Momentum indicator presents an enticing opportunity, it is crucial for investors to exercise caution and conduct thorough analysis. Other factors such as market conditions, sector performance, and individual risk tolerance should also be taken into consideration. Consulting with qualified financial advisors can provide valuable guidance in making well-informed investment decisions.

Xtrackers Russell US Multifactor ETF (DEUS) exhibits an exciting momentum surge as its Momentum indicator ascends above the 0 level. This development suggests the stock has the potential to experience an uptrend in its price. The data-backed insights from A.I.dvisor, indicating a success rate of 84% in similar cases, provide a compelling case for considering this momentum shift. However, prudent investors should conduct their own research and seek professional advice to align investment decisions with their individual financial goals and risk tolerance.

Related Ticker: DEUS

Momentum Indicator for DEUS turns positive, indicating new upward trend

DEUS saw its Momentum Indicator move above the 0 level on July 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for DEUS just turned positive on July 27, 2026. Looking at past instances where DEUS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DEUS advanced for three days, in of 335 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 374 cases where DEUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DEUS moved out of overbought territory on July 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DEUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DEUS broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOG), Alphabet (NASDAQ:GOOGL), Microsoft Corp (NASDAQ:MSFT), Amazon.com (NASDAQ:AMZN), Broadcom Inc. (NASDAQ:AVGO), Meta Platforms (NASDAQ:META), Eli Lilly & Co (NYSE:LLY), Micron Technology (NASDAQ:MU).

Industry description

The investment seeks investment results that correspond generally to the performance, before fees and expenses, of the Russell 1000 Comprehensive Factor Index. The fund, using a "passive" or indexing investment approach, seeks investment results that correspond generally to the performance of the underlying index, which is designed to track the equity market performance of companies in the United States selected on the investment style criteria ("factors") of quality,value,momentum,low volatility and size. It will invest at least 80% of its total assets (but typically far more) in component securities of the underlying index. The fund is non-diversified.

Market Cap

The average market capitalization across the Xtrackers Russell US Multifactor ETF ETF is 87.75B. The market cap for tickers in the group ranges from 182.3M to 5.27T. NVDA holds the highest valuation in this group at 5.27T. The lowest valued company is ANGI at 182.3M.

High and low price notable news

The average weekly price growth across all stocks in the Xtrackers Russell US Multifactor ETF ETF was 95%. For the same ETF, the average monthly price growth was 61%, and the average quarterly price growth was 314%. MNST experienced the highest price growth at 93%, while TTD experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Xtrackers Russell US Multifactor ETF ETF was -31%. For the same stocks of the ETF, the average monthly volume growth was -1% and the average quarterly volume growth was -54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 51
Price Growth Rating: 45
SMR Rating: 54
Profit Risk Rating: 62
Seasonality Score: -30 (-100 ... +100)
View a ticker or compare two or three
DEUS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category MidCapBlend

Profile
Details
Category
Mid-Cap Blend
Address
DBX ETF TRUST345 PARK AVENUENew York
Phone
2122505883
Web
www.DWS.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of โ‚ฌ10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcommโ€™s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25โ€“$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientificโ€™s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSXโ€™s results set the benchmark against Medtronic and Strykerโ€”diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108โ€“120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazonโ€™s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazonโ€™s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lillyโ€™s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The companyโ€™s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY),ย AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5โ€“13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ยฅ1.81 trillion, up 3.7% YoY, on track for its full-year target of ยฅ2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.